San Francisco, CA – May 13, 2025 – VeriSIM Life, a trailblazer in artificial intelligence (AI)-powered drug development, is proud to announce that its Founder and CEO, Dr. Jo Varshney, has been named to the 2025 “100 Women in AI” list by Flybridge Capital Partners and XFactor Ventures.
San Francisco, CA – May 13, 2025 – VeriSIM Life, a trailblazer in artificial intelligence (AI)-powered drug development, is proud to announce that its Founder and CEO, Dr. Jo Varshney, has been named to the 2025 “100 Women in AI” list by Flybridge Capital Partners and XFactor Ventures.
San Francisco, CA – April 14, 2025 – VeriSIM Life, a leading innovator in artificial intelligence (AI) for drug development, is proud to announce that it has been honored with the "Best AI-Driven Drug Development Engine 2025 - USA" award at the prestigious Global Health & Pharma (GHP) Biotechnology & Lifesciences Awards.
San Francisco, CA – April 14, 2025 – VeriSIM Life, a leading innovator in artificial intelligence (AI) for drug development, is proud to announce that it has been honored with the "Best AI-Driven Drug Development Engine 2025 - USA" award at the prestigious Global Health & Pharma (GHP) Biotechnology & Lifesciences Awards.
San Francisco, California - March 18th, 2025 - VeriSIM Life is proud to announce that their CEO, Dr. Varshney, has been named a finalist for the 'Executive Leader Award - Woman Executive of the Year' in the Women in AI Awards North America 2025. This prestigious award recognizes outstanding leadership and significant contributions to the field of artificial intelligence.
San Francisco, California - March 18th, 2025 - VeriSIM Life is proud to announce that their CEO, Dr. Varshney, has been named a finalist for the 'Executive Leader Award - Woman Executive of the Year' in the Women in AI Awards North America 2025. This prestigious award recognizes outstanding leadership and significant contributions to the field of artificial intelligence.
.png)
AtlasGEN Novel Drug Designer efficiently identifies new molecules based on favorable chemical properties and simultaneously evaluates them for clinical safety and effectiveness based on biology using VeriSIM Life’s groundbreaking Translational Index™ technology.
Iterative ranking of target engaging hits by their Translational Index values reduces the time and cost associated with other computational hit discovery approaches, while compressing the hit-to-lead refinement and optimization process by pre-validating hits for translatability. This unique integration dramatically reduces the number of compounds to evaluate in subsequent experimental research.
The ability to generate target engaging compound hits depends largely on the size of the molecular search library. The AtlasGEN search space is supported by more than 1 trillion compounds. Generative AI and deep learning techniques deliver unprecedented discovery capability.
AtlasGEN accurately predicts protein-lygand binding affinity by combining geometric conformer analysis with machine learning based on experimental data 72% more efficiently than molecular docking-based approaches.
.png)
